Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study on Acalabrutinib and Anti-CD20 Antibody in Patients With Predominantly Demyelinating Neuropathy With or Without Anti-MAG

NCT05065554 is registered in ClinicalTrials.gov with Shayna Sarosiek, MD as lead sponsor.

NCT NCT05065554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05065554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study on Acalabrutinib and Anti-CD20 Antibody in Patients With Predominantly Demyelinating Neuropathy With or Without Anti-MAG
Lead sponsor
Shayna Sarosiek, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 16, 2021
Completion date
October 1, 2028
Enrollment
12 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

igm mgus, neuropathy;peripheral, waldenstrom macroglobulinemia